Literature DB >> 27353670

WHO recommendations on shorter treatment of multidrug-resistant tuberculosis.

Giovanni Sotgiu1, Simon Tiberi2, Lia D'Ambrosio3, Rosella Centis4, Alimuddin Zumla5, Giovanni Battista Migliori6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27353670     DOI： 10.1016/S0140-6736(16)30729-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  13 in total

1.  Of Testing and Treatment: Implications of Implementing New Regimens for Multidrug-Resistant Tuberculosis.

Authors:  David W Dowdy; Grant Theron; Jeffrey A Tornheim; Robin Warren; Emily A Kendall
Journal:  Clin Infect Dis       Date:  2017-10-01       Impact factor: 9.079

2.  A new era for treatment of drug-resistant tuberculosis.

Authors:  Neel R Gandhi; James C M Brust; N Sarita Shah
Journal:  Eur Respir J       Date:  2018-10-04       Impact factor: 16.671

Review 3.  Would pan-tuberculosis treatment regimens be cost-effective?

Authors:  Emily A Kendall; Grania Brigden; Christian Lienhardt; David W Dowdy
Journal:  Lancet Respir Med       Date:  2018-05-31       Impact factor: 30.700

4.  High Treatment Success Rates Among HIV-Infected Multidrug-Resistant Tuberculosis Patients After Expansion of Antiretroviral Therapy in Botswana, 2006-2013.

Authors:  Sanghyuk S Shin; Chawangwa Modongo; Rosanna Boyd; Cynthia Caiphus; Lesego Kuate; Botshelo Kgwaadira; Nicola M Zetola
Journal:  J Acquir Immune Defic Syndr       Date:  2017-01-01       Impact factor: 3.771

Review 5.  Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis?

Authors:  Marcela Muñoz-Torrico; Adrian Rendon; Rosella Centis; Lia D'Ambrosio; Zhenia Fuentes; Carlos Torres-Duque; Fernanda Mello; Margareth Dalcolmo; Rogelio Pérez-Padilla; Antonio Spanevello; Giovanni Battista Migliori
Journal:  J Bras Pneumol       Date:  2016 Sep-Oct       Impact factor: 2.624

Review 6.  Recent developments in the diagnosis and management of tuberculosis.

Authors:  Giorgia Sulis; Rosella Centis; Giovanni Sotgiu; Lia D'Ambrosio; Emanuele Pontali; Antonio Spanevello; Alberto Matteelli; Alimuddin Zumla; Giovanni Battista Migliori
Journal:  NPJ Prim Care Respir Med       Date:  2016-11-03       Impact factor: 2.871

7.  Some Synonymous and Nonsynonymous gyrA Mutations in Mycobacterium tuberculosis Lead to Systematic False-Positive Fluoroquinolone Resistance Results with the Hain GenoType MTBDRsl Assays.

Authors:  Adebisi Ajileye; Nataly Alvarez; Matthias Merker; Timothy M Walker; Suriya Akter; Kerstin Brown; Danesh Moradigaravand; Thomas Schön; Sönke Andres; Viola Schleusener; Shaheed V Omar; Francesc Coll; Hairong Huang; Roland Diel; Nazir Ismail; Julian Parkhill; Bouke C de Jong; Tim E A Peto; Derrick W Crook; Stefan Niemann; Jaime Robledo; E Grace Smith; Sharon J Peacock; Claudio U Köser
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

8.  Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis.

Authors:  Emily A Kendall; Anthony T Fojo; David W Dowdy
Journal:  Lancet Respir Med       Date:  2016-12-16       Impact factor: 30.700

Review 9.  Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis.

Authors:  Ruvandhi R Nathavitharana; Patrick G T Cudahy; Samuel G Schumacher; Karen R Steingart; Madhukar Pai; Claudia M Denkinger
Journal:  Eur Respir J       Date:  2017-01-18       Impact factor: 16.671

10.  Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union.

Authors:  Marieke J van der Werf; Vahur Hollo; Csaba Ködmön; Masoud Dara; Mike Catchpole
Journal:  Eur Respir J       Date:  2017-03-22       Impact factor: 16.671
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.